Your browser doesn't support javascript.
loading
Early Modulation of Circulating MicroRNAs Levels in HER2-Positive Breast Cancer Patients Treated with Trastuzumab-Based Neoadjuvant Therapy.
Di Cosimo, Serena; Appierto, Valentina; Pizzamiglio, Sara; Silvestri, Marco; Baselga, José; Piccart, Martine; Huober, Jens; Izquierdo, Miguel; de la Pena, Lorena; Hilbers, Florentine S; de Azambuja, Evandro; Untch, Michael; Pusztai, Lajos; Pritchard, Kathleen; Nuciforo, Paolo; Vincent-Salomon, Anne; Symmans, Fraser; Apolone, Giovanni; de Braud, Filippo G; Iorio, Marilena V; Verderio, Paolo; Daidone, Maria Grazia.
Afiliação
  • Di Cosimo S; Biomarker Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, 20100 Milan, Italy.
  • Appierto V; Biomarker Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, 20100 Milan, Italy.
  • Pizzamiglio S; Bioinformatics and Biostatistics Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, 20100 Milan, Italy.
  • Silvestri M; Biomarker Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, 20100 Milan, Italy.
  • Baselga J; Vall D'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Piccart M; Department of Medical Oncology, Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B), 1000 Brussels, Belgium.
  • Huober J; Department of Obstetrics and Gynecology, University of Ulm, 89081 Ulm, Germany.
  • Izquierdo M; Novartis Pharmaceutical, 4002 Basel, Switzerland.
  • de la Pena L; SOLTI-Breast Cancer Research Group, 08035 Barcelona, Spain.
  • Hilbers FS; Breast International Group (BIG)-aisbl, 1000 Bruxelles, Belgium.
  • de Azambuja E; Department of Medical Oncology, Institut Jules Bordet and l'Université Libre de Bruxelles (U.L.B), 1000 Brussels, Belgium.
  • Untch M; Department of Gynecology and Obstetrics, Helios Klinikum Berlin-Buch, 13125 Berlin, Germany.
  • Pusztai L; Yale Cancer Center, Yale School of Medicine, New Haven, CT 06511, USA.
  • Pritchard K; Division of Medical Oncology, Department of Medicine, Sunnybrook Health Sciences Centre, Toronto, M4N 3M5 ON, Canada.
  • Nuciforo P; Vall D'Hebron Institute of Oncology, 08035 Barcelona, Spain.
  • Vincent-Salomon A; Groupe d'étude des facteurs pronostiques immunohistochimiques dans le cancer du sein, 75013 Unicancer, France.
  • Symmans F; Department of Pathology, The UT M.D. Anderson Cancer Center, Houston, TX 77030, USA.
  • Apolone G; Scientific Directorate, Fondazione IRCCS Istituto Nazionale dei Tumori, 20100 Milan, Italy.
  • de Braud FG; Department of Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, 20100 Milan, Italy.
  • Iorio MV; Molecular Targeting Unit, Department of Research, Fondazione IRCCS Istituto Nazionale dei Tumori, 20100 Milan, Italy.
  • Verderio P; Bioinformatics and Biostatistics Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, 20100 Milan, Italy.
  • Daidone MG; Biomarker Unit, Department of Applied Research and Technological Development, Fondazione IRCCS Istituto Nazionale dei Tumori, 20100 Milan, Italy.
Int J Mol Sci ; 21(4)2020 Feb 18.
Article em En | MEDLINE | ID: mdl-32085669
Assuntos
Palavras-chave
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptor ErbB-2 / Terapia Neoadjuvante / Trastuzumab / MicroRNA Circulante Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Int J Mol Sci Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Itália
Texto completo
Imprimir
XML
PubMed Links
Buscar no Google

Texto completo: 1 Coleções: 01-internacional Temas: Geral / Tipos_de_cancer / Outros_tipos Base de dados: MEDLINE Assunto principal: Neoplasias da Mama / Receptor ErbB-2 / Terapia Neoadjuvante / Trastuzumab / MicroRNA Circulante Tipo de estudo: Clinical_trials / Prognostic_studies / Risk_factors_studies Limite: Adult / Aged / Female / Humans / Middle aged Idioma: En Revista: Int J Mol Sci Ano de publicação: 2020 Tipo de documento: Article País de afiliação: Itália